Secretin (ChiRhoStim) Pancreas Perfusion for Pancreatic Adenocarcinoma

• Status: Terminated
• Trial end date: 2012-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to test if secretin-enhanced CT is a useful noninvasive screening tool for pancreatic cancer in a high-risk population.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mayo Clinic
• Collaborator: ChiRhoClin, Inc.
• Treatments: Secretin

Criteria

Inclusion Criteria:

• Persons 50 years or older with recently diagnosed diabetes (within 2 years), with at least one of the following: no family history of diabetes, abdominal discomfort, anorexia, weight loss, elevated serum CA 19-9, or those undergoing EUS with or without Fine Needle Aspiration (FNA) for pancreatic cancer screening ; OR

• Persons 35 years old or older with familial pancreatic cancer with 2 or more first degree relatives with pancreatic cancer; OR

• Persons 35 years old or older with Peutz-Jeghers syndrome; OR

• Persons 35 years old or older with suspicious clinical symptoms of pancreatic cancer, but had normal CT of the abdomen with iodinated contrast within 2 weeks.

Exclusion Criteria:

• Persons with contraindication to iodinated contrast

• Allergy to iodinated contrast

• Renal insufficiency (serum creatinine > 1.5 mg/dl)

• Patients with contraindication to ionizing radiation

• Pregnancy

• Patients with previous pancreatic surgery

• Contraindication to secretin

• Allergy to secretin

• Acute pancreatitis